Snyder to increase investment for clinical drug program split

DisperSol Technologies LLC announced that its Board of Directors appointed David S. Snyder as CFO as of October 1, 2020.

“David Snyder is a very comprehensive pharmaceutical finance executive with extensive experience in managing finance and expanding life sciences companies,” said Dr. Edward Rudnic, CEO of DisperSol Technologies. fast-growing company and to drive the next spin-out of DisperSol’s product portfolio assets. “

“This is an exclusive opportunity to enroll in the DisperSol team and attendance is based on the impressive achievements made to date,” said David S. Snyder. “With a Phase II product, two Phase I products, and a strong preclynic portfolio, DisperSol stands out for the productivity of its drug progression platform. I look forward to being a component of the team and advancing the company’s monetary strategy as personal and public capital to bring our healing products to patients. “

Mr. Snyder has more than 30 years of experience in the general and monetary control of public and personal corporations. Most recently, Mr. Snyder was CFO of Exicure, Inc. , a NASDAQ-listed clinical-stage biotechnology company. Prior to Exicure, Mr. Snyder was Executive Vice President and Chief Financial Officer of Cellular Dynamics International, Inc. (CDI), a NASDAQ-listed company that introduces new human mobiles used in drug discovery, toxicity testing, strains of mobile banking and mobile therapies. Prior to FujiFilm’s acquisition of CDI, Mr. Snyder was guilty of all finance, human resources and general leadership functions. In the past, Mr. Snyder served as Senior Vice President of Finance, Vice President of Site and CFO of Roche NimbleGen from 2007 to 2008. From 2006 to 2007, he was Vice President and CFO of NimbleGen Systems, Inc. At NimbleGen, Mr. Snyder helped prepare the company for an initial public offering and then helped manage the sale of NimbleGen to Roche. Prior to NimbleGen, he was CFO of public and personal corporations in the software, real estate, and diversified manufacturing industries. Mr. Snyder has been a director of Invenra, Inc. since 2012. He also served on the board of trustees of the University of Ottawa from 2012 to 2014.

Mr. Snyder earned a B. A. , summa cum laude, from the University of Ottawa and an M. B. A. with a wonderful difference from Harvard Business School, where he named the George Fisher Baker Fellow.

About DisperSol technologies

DisperSol is a clinically level drug progression company that aims to create new treatments for patients using its patented KinetiSol®. KinetiSol has been shown to be able to create new treatments from drugs with little bioavailability to provide exclusive clinical benefits to patients. The platform allows patients to expand medications when other characteristics do not make a difference. DisperSol’s active systems come with DST-0509 at the end of phase II for iron overload disorder, DST-2970 in middle phase 1 for refractory metastatic prostate cancer, and DST-8294 for the treatment of antiphospholipid syndrome. Other early-level systems come with DST-0058 and DST-5407, any of which are scheduled to enter clinical trials in 2021 for idiopathic pulmonary fibrosis and non-small mobile nonsquamous mobile lung cancer, respectively.

For more information, www. dispersoltech. com.

See the edition on businesswire. com: https://www. businesswire. com/news/home/20200924005132/fr/

contacts

Raj SheelVice President of Business Development and Marketing 512-686-5185raj. sheel@dispersoltech. com